LifeMD 2025 Revenue Jumps 25% to $194.1M, EBITDA Up 309%
LifeMD’s 2025 revenue rose 25% to $194.1 million with adjusted EBITDA up 309% to $15.3 million. The company launched oral Wegovy capturing 80% of new weight management patients, exited with $36.8 million cash and no debt, and readies benefits infrastructure to cover 220 million Americans.
1. Fourth Quarter and Full-Year 2025 Results
LifeMD reported full year 2025 revenue of $194.1 million, up 25% year-over-year, with adjusted EBITDA of $15.3 million, a 309% increase. Fourth quarter revenue rose 4% to $46.9 million and adjusted EBITDA jumped 348% to $4.8 million.
2. Oral Wegovy Launch and Weight Management Momentum
Subsequent to year-end, LifeMD launched its oral Wegovy offering, with over 80% of new weight management patients initiating branded GLP-1 therapy. First quarter patient sign-ups reached record levels at attractive acquisition costs.
3. Balance Sheet Strength and Infrastructure Expansion
LifeMD exited 2025 with $36.8 million in cash and zero debt, enabling accelerated investments in growth. Its benefits infrastructure is on track to cover approximately 220 million Americans by Q2 2026, supporting both self-pay and insured populations.
4. 2026 Financial Guidance
For Q1 2026, the company expects revenue of $48–49 million and an adjusted EBITDA loss of $4–5 million, returning to profitability in Q2. Full year 2026 revenue is guided at $220–230 million with adjusted EBITDA of $12–17 million as GLP-1 and women’s health initiatives mature.